Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4 and SRD5A2

European Journal of Human Genetics

Volumn 12, Issue 4, 2004, Pages 321-332

  Loukola, Anu ^a   Chadha, Monica ^a   Penn, Sharron G ^a   Rank, David ^a   Conti, David V ^b   Thompson, Deborah ^c   Cicek, Mine ^d   Love, Brad ^a   Bivolarevic, Vesna ^a   Yang, Qiner ^a   Jiang, Yalin ^a   Hanzel, David K ^a   Dains, Katherine ^a   Paris, Pamela L ^d   Casey, Graham ^d   Witte, John S ^b,c,e  

^a Amersham Biosciences   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Association; CYP17A1; CYP3A4; Genetic susceptibility; Haplotyping; Prostate cancer; SRD5A2

Indexed keywords

CYTOCHROME P450 17; CYTOCHROME P450 17A1; CYTOCHROME P450 3A4; GENE PRODUCT; SRD5A2 PROTEIN; TESTOSTERONE; UNCLASSIFIED DRUG;

ARTICLE; CANCER RISK; CONTROLLED STUDY; EVALUATION; FAMILY; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC DATABASE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TESTOSTERONE SYNTHESIS;

CASE-CONTROL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; GENOTYPE; HAPLOTYPES; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; STEROID 17-ALPHA-HYDROXYLASE; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 11144357976     PISSN: 10184813     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ejhg.5201101     Document Type: Article

References (43)

1. Smith DS, Bullock AD, Catalona WJ, Herschman JD: Racial differences in a prostate cancer screening study. J Urol 1996; 156: 1366-1369.
2. Hsing AW, Tsao L, Devesa SS: International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000; 85: 60-67.
3. McLellan DL, Norman RW: Hereditary aspects of prostate cancer. CMAJ 1995; 153: 895-900.
4. Neville PJ, Casey G, Witte JS: Hereditary prostate cancer and genetic risk; in Klein (ed): Managament of Prostate Cancer. New Jersey: Humana Press, Inc., 2003, 2nd edn.
5. Tavtigian SV, Simard J, Teng DH et al: A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet 2001; 27: 172-180.
6. Rebbeck TR, Walker AH, Zeigler-Johnson C et al: Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet 2000; 67: 1014-1019.
7. Suarez BK, Gerhard DS, Lin J et al: Polymorphisms in the prostate cancer susceptibility gene HPC2/ELAC2 in multiplex families and healthy controls. Cancer Res 2001; 61: 4982-4984.
8. Rokman A, Ikonen T, Mononen N et al: ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer. Cancer Res 2001; 61: 6038-6041.
9. Vesprini D, Nam RK, Trachtenberg J et al: HPC2 variants and screen-detected prostate cancer. Am J Hum Genet 2001; 68: 912-917.
10. Wang L, McDonnell SK, Elkins DA et al: Role of HPC2/ELAC2 in hereditary prostate cancer. Cancer Res 2001; 61: 6494-6499.
11. Xu J, Zheng SL, Carpten JD et al: Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. Am J Hum Genet 2001; 68: 901-911.
12. Carpten J, Nupponen N, Isaacs S et al: Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002; 30: 181-184.
13. Casey G, Neville PJ, Plummer SJ et al: RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 2002; 32: 581-583.
14. Rokman A, Ikonen T, Seppala EH et al: Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet 2002; 70: 1299-1304.
15. Wang L, McDonnell SK, Elkins DA et al: Analysis of the RNASEL gene in familial and sporadic prostate cancer. Am J Hum Genet 2002; 71: 116-123.
16. Colombel M, Olsson CA, Ng PY, Buttyan R: Hormone-regulated apoptosis results from reentry of differentiated prostate cells onto a defective cell cycle. Cancer Res 1992; 52: 4313-4319.
17. Gupta S, Ahmad N, Mohan RR, Husain MM, Mukhtar H: Prostate cancer chemoprevention by green tea: in vitro and in vivo inhibition of testosterone-mediated induction of ornithine decarboxylase. Cancer Res 1999; 59: 2115-2120.
18. Carey AH, Waterworth D, Patel K et al: Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994; 3: 1873-1876.
19. Waxman DJ, Lapenson DP, Aoyama T, Gelboin HV, Gonzalez FJ, Korzekwa K: Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch Biochem Biophys 1991; 290: 160-166.
20. Makridakis N, Ross RK, Pike MC et al: A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. Cancer Res 1997; 57: 1020-1022.
21. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Nat Cancer Inst 1998; 90: 1225-1229.
22. Lunn RM, Bell DA, Mohler JL, Taylor JA: Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRDSA2). Carcinogenetics 1999; 20: 1727-1731.
23. Makridakis NM, Ross RK, Pike MC et al: Association of missense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 1999; 354: 975-978.
24. Paris PL, Kupelian PA, Hall JM et al: Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev 1999; 8: 901-905.
25. Wadelius M, Andersson AO, Johansson JE, Wadelius C, Rane E: Prostate cancer associated with CYP17 genotype. Pharmacogenetics 1999; 9: 635-639.
26. Gsur A, Bernhofer G, Hinteregger S et al: A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int J Cancer 2000; 87: 434-437.
27. Habuchi T, Liqing Z, Suzuki T et al: Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res 2000; 60: 5710-5713.
28. Jaffe JM, Malkowicz SB, Walker AH et al: Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Res 2000; 60: 1626-1630.
29. Kittles RA, Panguluri RK, Chen W et al: CYP17 promoter variant associated with prostate cancer aggressiveness in African Americans. Cancer Epidemiol Biomarkers Prev 2001; 10: 943-947.
30. Nam RK, Toi A, Vesprini D et al: V89L polymorphism of type-2,5-alpha reductase enzyme gene predicts prostate cancer presence and progression. Urology 2001; 57: 199-204.
31. Stanford JL, Noonan EA, Iwasaki L et al: A polymorphism in the CYP17 gene and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2002; 11: 243-247.
32. Collins FS, Brooks LD, Chakravarti A: A DNA polymorphism discovery resource for research on human genetic variation. Genome Res 1998; 8: 1229-1231.
33. Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978-989.
34. Breslow NE, Day NE: Statistical methods in cancer research. Vol I - The analysis of case-control studies. IARC Sci Publ 1980; 32: 5-338.
35. Herman-Giddens M, Wang L, Koch G: Secondary sexual characteristics in boys: estimates from the national health and nutrition examination survey III, 1988-1994. Arch Pediatr Adolescent Med 2001; 155: 1022-1028.
36. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B: Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 1986; 76: 45-48.
37. Chang B, Zheng SL, Isaacs SD et al: Linkage and association of CYP17 in hereditary and sporadic prostate cancer. Int J Cancer 2001; 95: 345-359.
38. Haiman CA, Stampfer MJ, Giovannucci E et al: The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol Biomarkerse Prev 2001; 10: 743-748.
39. Ntais C, Polycarpou A, Ioannidis JP: Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Preve 2003; 12: 120-126.
40. Plummer SJ, Conti DV, Paris PL, Curran AP, Casey G, Witte JS: CYP3A4 and CYP3A5 genotypes, haplotypes and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 928-932.
41. Lubin JH, Hartge P: Excluding controls: misapplications in case-control studies. Am J Epidemiol 1984; 120: 791-793.
42. Poole C: Controls who experienced hypothetical causal intermediates should not be excluded from case-control studies. Am J Epidemiol 1999; 150: 547-551.
43. Thomas DC, Witte JS: Population stratification: a problem for case-control studies of candidate gene associations? Cancer Epidemiol Biomarkers Prev 2002; 11: 505-512.